Exclude Patient Type Detail Header
No
Footnote
<sup>1</sup> Established ASCVD warrants strong recommendation, while high-risk indicators warrant a weaker recommendation. Plus, higher absolute risk redux (lower NNT) seen at higher levels of baseline risk and should be factored into decision-making.<br><br>
<sup>2</sup> ASCVD is defined differently across CV outcomes trials, but all included those w/ established CVD (MI, stroke, any revascularization procedure). Variably included conditions like TIA, unstable angina, amputation, symptomatic or asymptomatic CAD.<br><br>
<sup>3</sup> High-risk indicators: Definitions vary, mostly comprise ≥55 yo w/ ≥2 additional RFs (including obesity, smoking, dyslipidemia, albuminuria).<br><br>
<sup>4</sup> For GLP-1 RAs, CV outcomes trials show their efficacy in reducing composite MACE, CV death, all-cause mortality, MI, stroke, and renal endpoints in pts w/ T2DM and established/high risk for CVD.<br><br>
<sup>5</sup> A low-dose TZD may be better tolerated w/ similar efficacy.<br><br>
<sup>6</sup> For SGLT2is, CV/renal trials show their efficacy in reducing risk of composite MACE, CV death, all-cause mortality, MI, hospitalization for HF, and renal outcomes in pts w/ T2DM and established/high risk for CVD.<br><br>
<sup>7</sup> CKD = eGFR <60 mL/min/1.73m<sup>2</sup> OR albuminuria (ACR ≥3.0 mg/mmol (30 mg/g)). Since eGFR and albuminuria may vary over time, repeat measurements are needed to document CKD.<br><br>
<sup>8</sup> Use SGLT2i in pts w/ eGFR ≥20 mL/min/1.73m<sup>2</sup>. Once started, continue until dialysis or transplantation.
<sup>2</sup> ASCVD is defined differently across CV outcomes trials, but all included those w/ established CVD (MI, stroke, any revascularization procedure). Variably included conditions like TIA, unstable angina, amputation, symptomatic or asymptomatic CAD.<br><br>
<sup>3</sup> High-risk indicators: Definitions vary, mostly comprise ≥55 yo w/ ≥2 additional RFs (including obesity, smoking, dyslipidemia, albuminuria).<br><br>
<sup>4</sup> For GLP-1 RAs, CV outcomes trials show their efficacy in reducing composite MACE, CV death, all-cause mortality, MI, stroke, and renal endpoints in pts w/ T2DM and established/high risk for CVD.<br><br>
<sup>5</sup> A low-dose TZD may be better tolerated w/ similar efficacy.<br><br>
<sup>6</sup> For SGLT2is, CV/renal trials show their efficacy in reducing risk of composite MACE, CV death, all-cause mortality, MI, hospitalization for HF, and renal outcomes in pts w/ T2DM and established/high risk for CVD.<br><br>
<sup>7</sup> CKD = eGFR <60 mL/min/1.73m<sup>2</sup> OR albuminuria (ACR ≥3.0 mg/mmol (30 mg/g)). Since eGFR and albuminuria may vary over time, repeat measurements are needed to document CKD.<br><br>
<sup>8</sup> Use SGLT2i in pts w/ eGFR ≥20 mL/min/1.73m<sup>2</sup>. Once started, continue until dialysis or transplantation.
Detail Type
Text
Detail Text
Patient Type Detail Header (Long)
Undertake cardiorenal risk redux while considering healthy lifestyle behaviors, DM self-mgmt education and support (DSMES), and social determinants of health (SDOH).